Worldwide Clinical Trials Partners With Every Cure
Worldwide Clinical Trials (Worldwide) has partnered with Every Cure.
Through this new partnership, Worldwide will serve as Every Cure’s clinical trial and drug development partner. The CRO will use its clinical development and rare disease know-how to assist in identifying links between rare diseases and generic drugs on the market—all facilitated through the nonprofit’s open-source database of drug-repurposing opportunities.
Every Cure was co-founded by Dr. David Fajgenbaum, Dr. Grant Mitchell, and Tracey Sikora in 2022.
Reference
Worldwide Clinical Trials Partners with Every Cure to Accelerate Discovery of Treatments for Rare Disease Patients. (2023, May 11). Business Wire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
